Meningococcal group b vaccine (4cmenb)

PBAC's latest decision on Meningococcal group b vaccine (4cmenb): Noted (2013). Considered for Active immunisation against disease caused by Neisseria meningitidis group B strains in individuals from 2 months of age and older. The submission requested inclusion in the National Immunisation Program with a routine 3+1 schedule in infants, a 2-dose course in adolescents, and a catch-up program in older infants, toddlers and adolescents.

Eligible population

Infants from 2 months of age (receiving 3 primary doses at 2, 4, 6 months and a booster at 12 months) and adolescents aged 11-17 years (receiving 1, 2, or 3 doses).

Therapy area

Vaccines

Line of therapy

Not applicable

Evidence base

RCT

Primary endpoint

Surrogate

Pivotal trial size

3,630 patients

Key trials

V72P12, V72P13, V72P10, V72P12E1, V72P13E1, V72P10E1, V72_29

Comparator

no vaccination

Economic model

Not modelled

ICER note

No economic evaluation / ICER presented in this public summary document.

Similar precedents

• Meningococcal group b vaccine, multicomponent (4cmenb)
  similarity 0.91
• Meningococcal group b vaccine (recombinant, adsorbed)
  similarity 0.87
• Meningococcal (groups a, c, w-135 and y) oligosaccharide crm197 conjugate vaccine
  similarity 0.74
• Meningococcal polysaccharide conjugate vaccine serogroups a, c, w-135 and y
  similarity 0.71
• Meningococcal polysaccharide serogroups a, c, w-135 and y conjugate vaccine
  similarity 0.71
• Hepatitis b surface antigen recombinant vaccine
  similarity 0.67